AMAG Pharma (AMAG) Reports Statistically Significant Data from IDA-303
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Leerink Swann Raises PT on AMAG Pharmaceuticals
March 15, 2013 1:02 PM EDTLeerink Swann today maintained an Outperform rating on AMAG Pharmaceuticals (NASDAQ: AMAG) and raised its price target to $23.00 (from $20.00).
This morning AMAG reported positive data from an extension study evaluating repeat dosing with Feraheme in patients with persistent or recurring iron deficiency... More
